Researchers survey Weight-Loss drug users to understand Real-World experiences
NCT ID NCT07154238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects information through online surveys from about 2,500 adults in Australia, Germany, UAE, and Spain who have been prescribed injectable semaglutide for weight management. The goal is to understand their characteristics, treatment experiences, and changes in weight and quality of life. No new treatment or lab tests are involved; it is purely a research survey.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,546 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study will collect quantitative and qualitative data from individuals treated with injectable semaglutide for weight management in real-world settings. The study will include two groups of participants: 1. Individuals who belong to or are recruited to an opt-in panel in the countries of interest and who have initiated injectable semaglutide for weight management. They will be classified according to the time when they first initiated treatment with injectable semaglutide for weight management. 2. HCPs who prescribe injectable semaglutide for weight management will be recruited from an existing opt-in panel in the countries of interest.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Age above or equal to 18 years at the time of providing informed consent. 3. Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain. 4. Have been prescribed and initiated injectable semaglutide for weight management prior to study screening. * For an eligible participant (HCPs), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Practice in a participating country: Australia, Germany, UAE, and Spain. 3. See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month. 4. Treat at least 10 adult patients per month for weight management. 5. Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs). 6. Prescribe injectable semaglutide for weight management. 7. Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others. Exclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no". 1. Unwillingness or language barriers precluding adequate understanding or cooperation. 2. Is currently or planning to become pregnant in next six months. 3. Is taking injectable semaglutide for Type 2 diabetes management only. * For an eligible participant (HCPs), all exclusion criteria must be answered "no". 1. Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview. 2. Unwillingness or language barriers precluding adequate understanding or cooperation. 3. Only treats patients under 18 years of age.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Novo Nordisk Investigational Site
Bad Oeynhausen, 32545, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?
- Can a cold cloth on the neck calm Post-Surgery nausea?